Asset Details
Do you wish to reserve the book?
P078/182 The derivo 2 heal embolization device in the treatment of ruptured and unruptured intracranial aneurysms: a retrospective multicenter analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P078/182 The derivo 2 heal embolization device in the treatment of ruptured and unruptured intracranial aneurysms: a retrospective multicenter analysis
Do you wish to request the book?
P078/182 The derivo 2 heal embolization device in the treatment of ruptured and unruptured intracranial aneurysms: a retrospective multicenter analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P078/182 The derivo 2 heal embolization device in the treatment of ruptured and unruptured intracranial aneurysms: a retrospective multicenter analysis
2023
Overview
IntroductionThe Derivo 2 Flow diverter has been previously described for the treatment of intracranial aneurysms. To overcome the risk of in-stent thrombosis and thrombo-embolism the device was modified by adding an anti-thrombogenic fibrin-heparin coating. The fibrin network aims at surface passivation, reduction of inflammatory reactions and endothelial healing. The covalently bound heparin reduces the thrombogenicity by inhibiting the platelet activation and the coagulation cascade.Aim of StudyTo assess the safety and effectiveness of the Derivo 2 heal (D2H) Flow diverter.MethodsWe performed a retrospective multicenter trial at seven neurovascular centers. Patients treated with the D2H for unruptured or ruptured intracranial aneurysms were included in the study. The primary endpoint was angiographic aneurysm occlusion at six months assessed by the O’Kelly-Marotta scale. Clinical outcome was evaluated after intervention and at six months, with major morbidity defined as modified Rankin Scale scores of 3–5.Results17 Patients with available follow-up were subjected to a preliminary analysis. All patients received standard of care antiplatelet therapy according to the respective institutions, with no deviations being reported. Mean aneurysm size was 12 mm. Sufficient aneurysm occlusion (OKM C-D) at six months angiographic follow-up was observed in 88.2%. Device displacement and proximal fish-mouthing occurred in 1 patient with no clinical sequelae. Neither in-stent thrombosis nor in-stent stenosis were detected.ConclusionThe Derivo 2 heal Flow Diverter is a promising antithrombogenic coated device for the treatment of intracranial aneurysms. Early post-interventional and long-term results will provide insight into the effect of antithrombogenicity and endothelial healing.Disclosure of InterestHannes Nordmeyer and Daniel Behme received speaker honoraria from Acandis. All other authors have nothing to declare.
Publisher
BMJ Publishing Group LTD
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.